Publicaciones en colaboración con investigadores/as de Pfizer (United States) (1)

2022

  1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93